Is Exenatide a Treatment for Parkinson's Disease?

Journal of Parkinson's Disease

Volumn 7, Issue 3, 2017, Pages 451-458

  Athauda, Dilan ^a   Wyse, Richard ^b   Brundin, Patrik ^c   Foltynie, Thomas ^a  

^a NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^b Cure Parkinson's Trust   (United Kingdom)

^c VAN ANDEL RESEARCH INSTITUTE   (United States)

Author keywords

Clinical trial; disease modification; exenatide; glucagon like peptide 1 agonist; insulin resistance; neuroprotection; Parkinson's disease

Indexed keywords

EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; PLACEBO; ANTIPARKINSON AGENT; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; PEPTIDE; VENOM;

ARTICLE; COGNITION; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; HUMAN; MOOD DISORDER; MOTOR PERFORMANCE; NEUROPROTECTION; OUTCOME ASSESSMENT; PARKINSON DISEASE; PATIENT SELECTION; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; X-RAY COMPUTED TOMOGRAPHY; AGONISTS; METABOLISM; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME;

ANTIPARKINSON AGENTS; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; HUMANS; PARKINSON DISEASE; PEPTIDES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME; VENOMS;

EID: 85027417002     PISSN: 18777171     EISSN: 1877718X     Source Type: Journal    
DOI: 10.3233/JPD-171192     Document Type: Article

References (16)

1. Hölscher C (2014) Central effects of GLP-1: New opportunities for treatments of neurodegenerative diseases. J Endocrinol, 221, T31-41.
2. Aviles-Olmos I, Dickson J, Kefalopoulou Z, Djamshidian A, Ell P, Soderlund T, Whitton P,Wyse R, Isaacs T, Lees A, Limousin P, & amp; Foltynie T (2013) Exenatide and the treatment of patients with Parkinson's disease. J Clin Invest, 123, 2730-2736.
3. Aviles-Olmos I, Dickson J, Kefalopoulou Z, Djamshidian A, Kahan J, Fmedsci PE, Whitton P,Wyse R, Isaacs T, Lees A, Limousin P, & amp; Foltynie T (2014) Motor and cognitive advantages persist 12 months after Exenatide exposure in Parkinson's disease. J Parkinsons Dis, 4, 337-344.
4. Athauda D, Maclagan K, Skene SS, Bajwa-joseph M, Letchford D, Chowdhury K, Hibbert S, Budnik N, Zampedri L, Dickson J, Li Y, Aviles-olmos I, Warner TT, Limousin P, Lees AJ, Greig NH, & amp; Tebbs S (2017) A randomised, double-blind, placebo controlled trial of Exenatide onceweekly in Parkinson's disease. Lancet, in press.
5. Kalia LV, Kalia SK, & amp; Lang AE (2015) Disease-modifying strategies for Parkinson's disease. Mov Disord, 30, 1442-1450.
6. Athauda D, & Foltynie T (2014) The ongoing pursuit of neuroprotective therapies in Parkinson disease. Nat Rev Neurol, 11, 25-40.
7. Kordower JH, Olanow CW, Dodiya HB, Chu Y, Beach TG, Adler CH, Halliday GM, & amp; Bartus RT (2013) Disease duration and the integrity of the nigrostriatal system in Parkinson's disease. Brain, 136, 2419-2431.
8. Noyce AJ, Nagy A, Acharya S, Hadavi S, Bestwick JP, Fearnley J, Lees AJ, & amp; Giovannoni G (2014) Bradykinesiaakinesia incoordination test: Validating an online keyboard test of upper limb function. PLoS One, 9, e96260.
9. Kas A, Payoux P, Habert M-O, Malek Z, CointepasY, Fakhri GEl, Chaumet-Riffaud P, Itti E, & RemyP (2007)Validation of a standardized normalization template for statistical parametric mapping analysis of 123 I-FP-CIT images. J Nucl Med, 48, 1459-1467.
10. Athauda D, & amp; Foltynie T (2016) Insulin resistance and Parkinson's disease: A new target for disease modification? Prog Neurobiol, 145, 98-120.
11. Baggio LL, & Drucker DJ (2007) Biology of incretins: GLP-1 and GIP. Gastroenterology, 132, 2131-2157.
12. Goldin M, & amp; Segal M (2003) Protein kinase C and ERK involvement in dendritic spine plasticity in cultured rodent hippocampal neurons. Eur J Neurosci, 17, 2529-2539.
13. Thomas GM, & amp; Huganir RL (2004) MAPK cascade signalling and synaptic plasticity. Nat Rev Neurosci, 5, 173-183.
14. Harkavyi A, Abuirmeileh A, Lever R, Kingsbury AE, Biggs CS, & Whitton PS (2008) Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson's disease. J Neuroinflammation, 5, 19.
15. Ventorp F, Bay-Richter C, Nagendra AS, Janelidze S, Matsson VS, Lipton J, Nordström U, Westrin A, Brundin P, & amp; Brundin L (2017) Exendin-4 treatment improves LPS-induced depressive-like behavior without affecting pro-inflammatory cytokines. J Parkinsons Dis, 7, 263-273.
16. Kim KS, Park DH, Wessel TC, Song B, Wagner JA, & amp; Joh TH (1993) A dual role for the cAMP-dependent protein kinase in tyrosine hydroxylase gene expression. Proc Natl Acad Sci U S A, 90, 3471-3475.